News & Updates

Show Multimedia Only

$Durable responses seen with axatilimab in recurrent/refractory GVHD$

Durable responses seen with axatilimab in recurrent/refractory GVHD

29 Jan 2024 by

The anti–CSF-R1 antibody axatilimab offers rapid and durable responses in patients with recurrent/refractory chronic graft-versus-host disease (GVHD) in the pivotal phase II AGAVE-201 trial.

Durable responses seen with axatilimab in recurrent/refractory GVHD

29 Jan 2024

Avelumab with paclitaxel plus ramucirumab shows promise in esophagogastric adenocarcinoma

27 Jan 2024

Combining the programmed cell death ligand 1 (PDL-1) inhibitor avelumab with paclitaxel plus ramucirumab appears to be efficacious and safe in the second-line treatment of metastatic esophagogastric adenocarcinoma, as shown in the phase II nonrandomized RAP trial.

Avelumab with paclitaxel plus ramucirumab shows promise in esophagogastric adenocarcinoma

27 Jan 2024

Cetuximab stored in vials, bags for days remains stable

25 Jan 2024 by

A recent study has demonstrated the extended physicochemical stability of cetuximab in opened vials and infusion bags, which can help save costs for healthcare providers.

Cetuximab stored in vials, bags for days remains stable

25 Jan 2024

PRS enhances ultrasound-based assessment of thyroid nodules

24 Jan 2024

A recent study suggests that an ultrasound-based classification of thyroid nodules as either benign or malignant can improve its diagnostic accuracy by combining it with polygenic risk scores (PRS).

PRS enhances ultrasound-based assessment of thyroid nodules

24 Jan 2024

Delayed postoperative radiation tied to higher recurrence, death in MCC

23 Jan 2024

Delays in postoperative radiation therapy (PORT) may lead to increased locoregional recurrence (LRR), usually occurring beyond the radiation field, among patients with Merkel cell carcinoma (MCC), as shown in a recent study.

Delayed postoperative radiation tied to higher recurrence, death in MCC

23 Jan 2024

Adding bevacizumab to chemo enhances antitumour activity in children with R/R neuroblastoma

23 Jan 2024 by

Adding bevacizumab (B) to temozolomide (T)-based chemotherapy increases overall response rate (ORR) in children with relapsed/refractory (R/R) neuroblastoma, according to results of the three-by-two factorial, randomized controlled phase II BEACON-Neuroblastoma trial.

Adding bevacizumab to chemo enhances antitumour activity in children with R/R neuroblastoma

23 Jan 2024

The 100,000 Genomes Project: Insights from the cancer programme

22 Jan 2024 by

Recently published data from the cancer programme of the 100,000 Genomes Project, which maps out the genomic patterns of patients with different cancer types using whole-genome sequencing (WGS), have provided insights on integrating genomics into routine cancer care.

The 100,000 Genomes Project: Insights from the cancer programme

22 Jan 2024

Cancer survivors may benefit from social media-based interventions

22 Jan 2024 by

A meta-analysis and meta-regression of randomized controlled trials (RCTs) found that social media-based interventions – which are interventions from any form of online medium that enables participant interaction (eg, Facebook, Instagram, TikTok, Twitter) – may be beneficial for cancer patients.

Cancer survivors may benefit from social media-based interventions

22 Jan 2024

Capivasertib fits the bill for HR+, HER2– ABC

22 Jan 2024 by

Capivasertib, when added to fulvestrant, prolonged progression-free survival (PFS) by 4.1 months in an analysis of Chinese patients with hormone receptor–positive (HR+), HER2-negative (HER2– ABC) advanced breast cancer (ABC) whose disease had progressed on aromatase inhibitor, with or without a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor in the phase III CAPItello-291 trial.

Capivasertib fits the bill for HR+, HER2– ABC

22 Jan 2024

Cancer diagnosis in children ups risk of parental suicide attempt

21 Jan 2024 by

The risk of suicide attempts among parents of children with cancer is higher during the first years following cancer diagnosis, particularly when the child is diagnosed at age 18 years or below, or with an aggressive or fatal form of cancer, a study has found.

Cancer diagnosis in children ups risk of parental suicide attempt

21 Jan 2024

News & Updates

Showing Oncology articles

Showing

Specialty:

Durable responses seen with axatilimab in recurrent/refractory GVHD

Durable responses seen with axatilimab in recurrent/refractory GVHD

Avelumab with paclitaxel plus ramucirumab shows promise in esophagogastric adenocarcinoma

Avelumab with paclitaxel plus ramucirumab shows promise in esophagogastric adenocarcinoma

Cetuximab stored in vials, bags for days remains stable

Cetuximab stored in vials, bags for days remains stable

PRS enhances ultrasound-based assessment of thyroid nodules

PRS enhances ultrasound-based assessment of thyroid nodules

Delayed postoperative radiation tied to higher recurrence, death in MCC

Delayed postoperative radiation tied to higher recurrence, death in MCC

Adding bevacizumab to chemo enhances antitumour activity in children with R/R neuroblastoma

Adding bevacizumab to chemo enhances antitumour activity in children with R/R neuroblastoma

The 100,000 Genomes Project: Insights from the cancer programme

The 100,000 Genomes Project: Insights from the cancer programme

Cancer survivors may benefit from social media-based interventions

Cancer survivors may benefit from social media-based interventions

Capivasertib fits the bill for HR+, HER2– ABC

Capivasertib fits the bill for HR+, HER2– ABC

Cancer diagnosis in children ups risk of parental suicide attempt

Cancer diagnosis in children ups risk of parental suicide attempt